Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease

American Journal of Surgical Pathology

Volumn 30, Issue 8, 2006, Pages 1022-1029

  Levi, Gabriel S ^a   Harpaz, Noam ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Dysplasia; Inflammatory bowel disease; Low grade tubuloglandular adenocarcinoma

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 2; MUCIN 6; PROTEIN MLH1;

ADULT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; COLORECTAL CARCINOMA; CROHN DISEASE; CYTOPATHOLOGY; DNA REPLICATION; ENTERITIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINAL LOW GRADE TUBULOGLANDULAR ADENOCARCINOMA; INTESTINE CARCINOMA; MALE; PALPATION; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; ULCERATIVE COLITIS;

ADENOCARCINOMA; ADULT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED;

EID: 33747585620     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200608000-00014     Document Type: Article

References (40)

1. Befrits R, Ljung T, Jaramillo E, et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002;45:615-620.
2. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
3. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71-74.
4. Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981;80:366-374.
5. Butt JH, Konishi F, Morson BC, et al. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. Dig Dis Sci. 1983;28:18-26.
6. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77-99.
7. Chang SK, Dohrman AF, Basbaum CB, et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology. 1994;107:28-36.
8. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994;107:934-944.
9. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994;35:1419-1423.
10. Dundas SA, Kay R, Beck S, et al. Can histopathologists reliably assess dysplasia in chronic inflammatory bowel disease? J Clin Pathol. 1987;40:1282-1286.
11. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
12. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001;194:152-157.
13. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336:357-359.
14. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000;60:4864-4868.
15. Gillen CD, Andrews HA, Prior P, et al. Crohn's disease and colorectal cancer. Gut. 1994;35:651-655.
16. Harpaz N. Adenoma-like dysplastic polyps in inflammatory bowel disease. Pathol Case Rev. 2004;9:135-141.
17. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339-357.
18. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634-1648.
19. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
20. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci. 1989;34:1536-1541.
21. Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403-410.
22. Lewin KJ, Riddel RH, Weinstein WM. Gastrointestinal Pathology and its Clinical Implications. New York, Tokyo: Igaku-Shoin; 1992.
23. Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003;52:1127-1132.
24. Lindberg B, Persson B, Veress B, et al. Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol. 1996;31:1195-1204.
25. Mayer R, Wong WD, Rothenberger DA, et al. Colorectal cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum. 1999;42:343-347.
26. McGregor DK, Wu TT, Rashid A, et al. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004;28:712-718.
27. Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology. 1988;95:668-675.
28. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993;105:1716-1723.
29. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology. 1991;100:1241-1248.
30. Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002;15:379-386.
31. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
32. Riddell RH, Petras R, Williams GT, et al. Tumors of the Intestines. Washington, DC: Armed Forces Institute of Pathology; 2003.
33. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology. 1985;89:1342-1346.
34. Schulmann K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology. 2005;129:74-85.
35. Shia J, Ellis NA, Klimstra DS. The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch. 2004;445:431-441.
36. Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg. 1993;218:189-195.
37. Taylor BA, Pemberton JH, Carpenter HA, et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum. 1992;35:950-956.
38. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311-1319.
39. Ullman T, Itzkowitz SH. In: Satsangi J, Sutherland L R, eds. Inflammatory Bowel Diseases. 4th ed. Philadelphia: Churchill Livingstone; 2003:605-620.
40. Weiss AA, Babyatsky MW, Ogata S, et al. Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem. 1996;44:1161-1166.